A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

Geneva-based Neurosterix’s lead drug candidate is a selective muscarinic M4 positive allosteric modulator (PAM) with potential as a treatment for schizophrenia, and it will also work on a ...

Shanbhag and colleagues sought to examine the safety and efficacy of TAK-071 — muscarinic acetylcholineM1 positive allosteric modulator — in a small cohort of patients with PD as well as ...